RxDoctor Payments Data

Deirdre Smith

Family · Cranston, RINPI 1326032004

Payments from drug & device makers

$1,588in general payments, 2019–2025

Across 107 payments — averaging $14.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$497
  • Nestle Healthcare Nutrition Inc.$355
  • Mallinckrodt Hospital Products Inc.$132
  • Lundbeck LLC$125
  • Takeda Pharmaceuticals U.S.A., Inc.$118
  • Braintree Laboratories, Inc.$108
  • plus $254 from 8 others

What the payments were for

  • Food & beverage$1,588100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,588 in reported general payments places this provider in the 80th percentile of 457 family providers in Rhode Island.

See all family providers in Rhode Island

Medicare billing

Part B allowed, 2024
$51,870
Medicare patients
389
Services billed
557

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab16$128,545
CreonLipase/Protease/Amylase37$80,456
SimponiGolimumab11$78,177
XifaxanRifaximin19$59,877
LinzessLinaclotide46$52,832
Mesalamine32$17,016
Famotidine853$12,852
TrulancePlecanatide16$11,390
Dexlansoprazole DrDexlansoprazole47$10,370
Lansoprazole326$7,648
Omeprazole519$7,375
Pantoprazole Sodium450$5,578
Esomeprazole Magnesium153$5,208
Colestipol Hcl28$3,743
Sucralfate107$2,804

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$497$133,28883 claims
Johnson & JohnsonSimponi$28$78,17711 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$35$71,26735 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 457 family providers in Rhode Island.

Other family in Cranston

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →